Form 4: ARS Pharmaceuticals' Chief Medical Officer Sarina Tanimoto Reports Stock Sales
SEC Form 4 Filing
Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reported the sale of common stock shares across multiple transactions, as detailed in a recent SEC Form 4 filing.
Summary
- Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, filed a Form 4 with the SEC.
- The filing reports multiple sales of ARS Pharmaceuticals' common stock.
- These transactions occurred on June 11 and June 12, 2024.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan established on March 31, 2023.
- On June 11, 2024, 2,166 shares were sold at a weighted average price of $9.002, with prices ranging from $9.00 to $9.02.
- Another 1,972 shares were sold on the same day at a weighted average price of $9.0039, also with prices ranging from $9.00 to $9.02.
- On June 12, 2024, 47,834 shares were sold at a weighted average price of $9.1454, with prices ranging from $9.01 to $9.315.
- Additionally, 48,028 shares were sold on the same day at a weighted average price of $9.1447, with prices ranging from $9.01 to $9.315.
- Following these transactions, Tanimoto directly owns 3,407,847 shares.
- She also has indirect ownership through various trusts, including the Richard E. Lowenthal Charitable Remainder UniTrust and the Lowenthal-Tanimoto Family Trust.
- Tanimoto's spouse also holds shares, and she has indirect ownership through the Sarina Tanimoto Charitable Remainder UniTrust.
- Tanimoto disclaims beneficial ownership of shares held by the Richard E. Lowenthal Charitable Remainder UniTrust.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the stock sales were pre-planned under a 10b5-1 trading plan and do not necessarily reflect a negative outlook on the company's future.
Industry Context
This filing is a routine disclosure of insider trading activity. It's important to monitor such filings to understand the sentiment of company insiders regarding the stock's valuation and future prospects. However, sales under a pre-arranged 10b5-1 plan are less indicative of current sentiment than discretionary trades.
Stakeholder Impact
- The stock sales by a key executive could create uncertainty among shareholders.
- However, the pre-planned nature of the sales mitigates the potential negative impact.
Key Dates
| Date | Description |
|---|---|
| 2020-01-07 | Date of Richard E. Lowenthal Charitable Remainder UniTrust |
| 2006-04-03 | Date of Lowenthal-Tanimoto Family Trust U/A |
| 2023-03-31 | Date of Rule 10b5-1 trading plan |
| 2024-06-11 | Date of stock sale transactions |
| 2024-06-12 | Date of stock sale transactions |
| 2024-06-13 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.